EPO906 Therapy in Patients With Advanced Breast Cancer

Exclusion Criteria

• •Bone-only disease;
• •Symptomatic pleural effusions;
• •Symptomatic CNS metastases or leptomeningeal involvement;
• •Any peripheral neuropathy or unresolved diarrhea greater than Grade 1;
• •Severe cardiac insufficiency;
• •Patients taking Coumadin or other warfarin-containing agents with the exception of low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports;
• •History of another malignancy within 5 years prior to study entry except curatively treated non-melanoma ckin cancer or cervical cancer in situ;
• •Active or suspected acute or chronic uncontrolled infection including abcesses or fistulae;
• •HIV+ patients;
• •Pregnant or lactating females;
• •Patients who have had radiation, chemotherapy, or hormonal therapy within the last four (4) weeks excluding palliative radiotherapy to isolated peripheral bone metastases not being used as markers for efficacy;
• •Patients taking Herceptin less than three (3) weeks prior to study start.